Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
AdAlta Ltd. ( (AU:1AD) ) has provided an update.
AdAlta’s subsidiary AdCella has reported further positive clinical data from investigator-led trials in China of its Generation 2 CAR-T therapy BZDS1901 in advanced mesothelioma patients who had relapsed after or not responded to chemotherapy or immunotherapy. Fourteen patients have now received the Gen 2 product, with updated manufacturing enabling a shorter, lower-cost process and lower doses that improve scalability.
Among the 10 patients treated at the highest BZDS1901 doses, five achieved tumour shrinkage of more than 30%, implying a 50% overall response rate that is more than double typical second-line options. Two patients recorded complete disappearance of tumours on CT scans, an unusually high 20% complete response rate in this setting, and over a quarter of all treated patients showed ongoing tumour shrinkage, bolstering evidence of CAR-T persistence and supporting plans for higher dosing and further clinical development.
The most recent analyst rating on (AU:1AD) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on AdAlta Ltd. stock, see the AU:1AD Stock Forecast page.
More about AdAlta Ltd.
AdAlta Limited is an Australian biotechnology company developing next-generation cell and protein therapeutics, primarily through its cell therapy subsidiary AdCella. The group is focused on first-in-class CAR-T treatments targeting mesothelin, a protein overexpressed in aggressive solid tumours such as mesothelioma, certain lung cancers and various gynaecological cancers.
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$10.2M
See more data about 1AD stock on TipRanks’ Stock Analysis page.